Dr. David R. Camidge, MD

Dr. Camidge practices at UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth.

Dr. Camidge's NPI, 1336239912, was assigned on October 13, 2006. Dr. Camidge graduated from Oxford University Medical School in 1995. Dr. Camidge holds Colorado license 46519.

Dr. Camidge's primary practice is UCHealth University of Colorado Hospital, at 12605 E 16th Ave, Aurora, CO 80045 in Adams County. The practice phone is (720) 848-0000.

Dr. Camidge's primary practice is UCHealth University of Colorado Hospital in Aurora, Colorado, part of UCHealth. Dr. Camidge is also affiliated with UCHealth Highlands Ranch Hospital. The medical group on file is University of Colorado Medicine (CU Medicine). Dmand AI also links Dr. Camidge to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Camidge practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Camidge's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Camidge is licensed in Colorado.

Dmand AI lists lung cancer and prostate cancer among the conditions Dr. Camidge treats.

CMS data shows 224 Medicare services from Dr. Camidge across 2 procedure codes in 2024, all of them office visits, for 65 Medicare patients. Medicare paid $25,512 for them.

CMS counts 65 Medicare patients who saw Dr. Camidge in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have cancer, and 51% have high blood pressure. Their average risk score is 3.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Camidge's median patient age at 71, with 60% women.

In 2024, Dr. Camidge wrote 201 Medicare Part D claims for 32 patients. 67% of them were for generic drugs. CMS names the drug for 113 of them, across 5 drugs with 11 or more claims each, at $691,462 in total drug cost. In 2023, CMS named 148 claims across 6 drugs.

Dr. Camidge accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Camidge as offering telehealth.

Dmand AI links 203 papers to Dr. Camidge, published from 2008 to 2025. 2022 was the busiest year, with 18. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Protein Kinase Inhibitors. Dr. Camidge has published most often in J Thorac Oncol. Dr. Camidge's most frequent co-authors are Robert Doebele, MD, Sai-Hong I I. Ou, MD and Shirish Madhav Gadgeel, MD.

Dmand AI links Dr. Camidge to 4 clinical trials. 4 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Renal Cell. AbbVie sponsors the most, 3. Open Payments lists research payments to Dr. Camidge that name 5 trials.

CMS Open Payments shows 552 general payments to Dr. Camidge from 43 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Daiichi Sankyo Inc. paid the most, $162,957. It also lists 45 research payments totaling $45,549 from 2016 to 2025, naming 5 clinical trials.

Dmand AI lists 1 award for Dr. Camidge, most recently CMS Stage 1 EHR in 2013.

Dr. Camidge graduated from Oxford University Medical School in 1995.

Dr. Camidge is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.